Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Drug Evaluation × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2 Genitourinary 1 Gastrointestinal 1 CNS 1 Breast 1

Conditions

Upper Tract Urothelial Carcinomas 1

Interventions

Prednisone 110 Docetaxel 104 enzalutamide 82 pembrolizumab 76 Sunitinib 76 Leuprolide 75 Abiraterone Acetate 75 Gemcitabine 70 Nivolumab 67 Radiotherapy 48 Goserelin 46 Everolimus 46 Cisplatin 46 bicalutamide 45 Bevacizumab 44 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 39 Magnetic Resonance Spectroscopy 38 Carboplatin 37 Sorafenib 35 Paclitaxel 32 Radiosurgery 31 pazopanib 30 Ipilimumab 29 cabozantinib 27 atezolizumab 27 abiraterone 26 Cyclophosphamide 26 Axitinib 25 apalutamide 24 Radiation 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated

39 enrolled 31 charts

Upper Tract Urothelial Carcinomas

Data powered by HemOnc (CC BY 4.0) Colophon ⚡